Evaxion Biotech A/S (EVAX)

Neutral

Institutional ownership roughly stable: +0.03% change quarter-over-quarter.

Data as of Q1 2026

$3.22▲ 6.27%

EOD close · as of 2026-09-17

Market Cap

$1.34B

Enterprise Value

$1.34B

Revenue (FY)

—

Rev. growth

—

Gross margin

—

Net margin

—

ROIC

—

Debt / EBITDA

—

Revenue—

—

Net Income· FY2025-$7.7M

Free Cash Flow—

—

✓ Strengths

No standout strengths flagged.

△ Watch

Nothing notable to watch.

⚠ Risks

Unprofitable — Net loss

Deep analysis

Quality of the business

What backs the price

Is the profit real, and how strong is the balance sheet?

Income statement

How a revenue dollar becomes profit

FY2025 · every deduction from revenue to net income

Not enough detail.

Returns

Why ROE is —

DuPont — the three levers

Net margin

—

profit / rev

Asset turns

—

rev / assets

Leverage

—

assets / equity

ROE

—

return on equity

Watch the leverage lever — a chunk of ROE comes from the balance sheet.

Leverage & liquidity

Debt structure

What the company owes vs. what it holds

Total Debt

—

Cash & Equivalents

—

Net Debt

—

Net debt / EBITDA—

Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.

Operating leverage

How profit responds to sales

Latest year: profit growth vs revenue growth

Revenue Δ

—

Op. income Δ

—

Op. leverage

—

Operating leverage needs meaningful revenue change.

Operating leverage

Common-size income statement

Each line as % of revenue — the trend in color

% of revenue	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025

Green = margin-favorable vs the row's own range · red = unfavorable.

Track record · FY2018 → FY2025

How the ratios & debt developed

The metrics that matter, over time

ROE

—

— · latest

—

Net margin

—

— · latest

—

ROIC

—

— · latest

—

Gross margin

—

— · latest

—

Debt / EBITDA

—

— · latest

—

Current ratio

—

— · latest

—

FCF margin

—

— · latest

—

Free cash flow

—

— · latest

—

Institutional ownership: 16 holders · 0% of shares · 73th percentile crowding — Institutional ownership roughly stable: +0.03% change quarter-over-quarter. (see the 13F tab)

A 30-second read on EVAX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.

Loading snapshot...

Financials

$3.22▲ 6.27%

EOD close · as of 2026-09-17

Market Cap

$1.34B

Enterprise Value

$1.34B

Revenue → Profit Flow

How a revenue dollar becomes profit — FY2025

Not enough income-statement detail for a flow diagram.

No data reported for this breakdown.

Each value shows its share of revenue below it (common-size).

Line Item	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Research & Development	$10.0M	$10.5M	$11.9M	$17.1M	$19.6M	$10.9M	$8.2M	$3.7M
Selling, General & Admin	$6.8M	$7.6M	$10.4M	$8.2M	$6.3M	$5.7M	$2.6M	$1.9M
Interest Expense	$0	$0	$1K	$34K	$5K	$29K	$36K	$10K
Net Income	-$7.7M	-$10.6M	-$22.1M	-$23.2M	-$24.5M	-$15.0M	-$11.2M	-$5.5M

Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.

Loading financials...

EVAX vs. Healthcare peers

Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.

Where it ranks

top thirdmiddlebottompeer median

ValuationCheaper than peers scores higher

P / E

EVAX — · med 24.3× · best 0.0×

not enough peer data

—

P / S

EVAX — · med 3.7× · best 0.0×

not enough peer data

—

EV / EBITDA

EVAX — · med 17.7× · best -11.2×

not enough peer data

—

P / B

EVAX — · med 2.7× · best 0.0×

not enough peer data

—

GrowthLatest fiscal-year revenue vs prior year

Revenue growth (YoY)

EVAX — · med 8.7% · best 230195%

not enough peer data

—

ProfitabilityMargins vs the sector

Gross margin

EVAX — · med 58.6% · best 8891%

not enough peer data

—

Operating margin

EVAX — · med -40.2% · best 66.7%

not enough peer data

—

Net margin

EVAX — · med -33.6% · best 3203%

not enough peer data

—

FCF margin

EVAX — · med -15.3% · best 239%

not enough peer data

—

Returns on capitalHow hard the capital works

Return on equity

EVAX — · med -30.6% · best 101230%

not enough peer data

—

Return on invested capital

EVAX — · med -28.6% · best 101230%

not enough peer data

—

LeverageLess debt scores higher

Net debt / EBITDA

EVAX — · med -0.0× · best -122.1×

not enough peer data

—

13F convictionInstitutional breadth & ownership

13F holders

EVAX 16 · med 94 · best 4,451

19th pct

Institutional ownership

EVAX 0.1% · med 59.5% · best 1141%

7th pct

Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.

Peer table

Click a column to sort · latest FY

Company	Mkt cap ▼	P/E	EV/EBITDA	P/S	Rev gr	Gross	Net	ROE	ROIC	Net D/EBITDA	13F
BCAXBicara Therapeutics In…	$1.24T	—	—	—	—	—	—	-34.4%	-34.4%	—	143
LLYEli Lilly and Company	$1.03T	50.2×	—	15.9×	44.7%	83.0%	31.7%	77.8%	29.9%	—	4,193
AKTXAkari Therapeutics Plc	$894.1B	—	—	—	—	—	—	-61.1%	-61.1%	—	1
JNJJohnson & Johnson	$650.5B	24.5×	—	6.9×	6.0%	67.9%	28.5%	32.9%	20.7%	—	4,451
ABBVAbbVie Inc.	$467.1B	111.9×	33.4×	7.6×	8.6%	70.2%	6.9%	-129%	6.6%	4.2×	3,895
MRKMerck & Co., Inc.	$368.2B	20.2×	—	5.7×	1.3%	74.8%	28.1%	34.7%	17.9%	—	3,594
UNHUnitedHealth Group Inc…	$339.9B	28.4×	19.7×	0.8×	11.8%	88.7%	2.7%	12.0%	6.8%	3.9×	2,891
AZNAstraZeneca PLC	$257.7B	—	—	—	—	—	—	—	—	—	1,248
TMOThermo Fisher Scientif…	$248.2B	37.1×	31.9×	5.6×	3.9%	—	15.0%	12.6%	7.0%	4.9×	2,481
AMGNAmgen Inc.	$204.6B	26.7×	17.6×	5.6×	10.0%	67.2%	21.0%	89.1%	12.2%	3.8×	3,014
GILDGilead Sciences, Inc.	$187.3B	22.3×	20.4×	6.4×	2.4%	78.8%	28.9%	37.5%	17.9%	2.4×	2,218
ABTAbbott Laboratories	$178.0B	27.5×	19.2×	4.0×	5.7%	56.4%	14.7%	12.5%	10.0%	1.4×	2,964
PFEPfizer Inc.	$157.1B	20.3×	—	2.5×	-1.6%	74.3%	12.4%	9.0%	5.1%	—	2,838
DHRDanaher Corporation	$150.2B	42.1×	31.0×	6.1×	2.9%	59.1%	14.7%	6.9%	5.1%	3.4×	2,083
ISRGIntuitive Surgical, In…	$136.2B	48.7×	37.5×	13.5×	20.5%	66.0%	28.4%	16.0%	16.0%	—	2,190
VRTXVertex Pharmaceuticals…	$131.1B	33.7×	28.8×	10.9×	8.9%	86.2%	32.9%	21.2%	21.2%	—	1,609
BMYBRISTOL-MYERS SQUIBB C…	$127.8B	18.2×	—	2.6×	-0.2%	71.1%	14.6%	38.2%	11.1%	—	2,431
MDTMedtronic plc	$118.8B	24.9×	12.6×	3.3×	8.4%	65.0%	13.2%	9.7%	9.4%	0.2×	2,114
CVSCVS Health Corporation	$114.7B	64.9×	11.5×	0.3×	7.8%	45.0%	0.4%	2.4%	2.4%	0.0×	1,795
SYKStryker Corporation	$107.1B	33.4×	18.4×	4.3×	11.2%	64.0%	12.9%	14.5%	8.5%	2.5×	2,196
MCKMcKesson Corporation	$102.5B	22.9×	16.2×	0.3×	12.4%	3.6%	1.2%	-219%	109%	1.0×	1,946
HCAHCA Healthcare, Inc.	$96.4B	15.1×	—	1.3×	7.1%	—	9.0%	-113%	16.8%	—	1,346
ELVElevance Health Inc.	$91.4B	16.4×	15.5×	0.5×	12.5%	89.4%	2.8%	12.9%	7.6%	4.2×	1,397
REGNRegeneron Pharmaceutic…	$82.6B	19.0×	19.8×	5.8×	1.0%	—	31.4%	14.4%	13.6%	0.5×	1,336
CICigna Corporation	$72.7B	12.4×	5.5×	0.3×	11.2%	21.8%	2.2%	14.3%	14.1%	0.0×	1,583
EVAXEvaxion Biotech A/S	$1.3B	—	—	—	—	—	—	—	—	—	16

Peers = companies sharing EVAX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.

Loading peer comparison...

Evaxion Biotech A/S (EVAX)

✓ Strengths

△ Watch

⚠ Risks

Deep analysis

What backs the price

How a revenue dollar becomes profit

Why ROE is —

Debt structure

How profit responds to sales

Common-size income statement

How the ratios & debt developed

Financials

Revenue → Profit Flow

Reverse DCF — what growth does the price assume?

Quality & Risk

Piotroski F-Score

Altman Z-Score

Beneish M-Score

Earnings quality

Solvency

Dividends & Returns

Is the payout covered?

Dividends + buybacks, per year

Debt & Leverage

Capital structure over time

Net debt / EBITDA

Debt servicing

Liquidity

Short-term vs long-term debt

Performance vs. S&P 500

Hover the chart to read any quarter

Annual return vs the market

Cumulative lead over the S&P 500

Drawdown from peak · max -100%

EVAX vs. Healthcare peers

Where it ranks

Peer table

Ownership Map

Buy / Sell Volume by Quarter

Institutional Trends (6 Quarters)

Institutional Holders

Institutional Holders

Buy / Sell Volume by Quarter

Institutional Trends (6 Quarters)

Reverse DCF — what growth does the price assume?

Performance vs. S&P 500

Hover the chart to read any quarter

Annual return vs the market

Cumulative lead over the S&P 500

Drawdown from peak · max -100%

Ownership Map

EVAX vs. Healthcare peers

Where it ranks

Peer table

Financials

Revenue → Profit Flow

Quality & Risk

Piotroski F-Score

Altman Z-Score

Beneish M-Score

Earnings quality

Solvency

Dividends & Returns

Is the payout covered?

Dividends + buybacks, per year

Debt & Leverage

Capital structure over time

Net debt / EBITDA

Debt servicing

Liquidity

Short-term vs long-term debt

✓ Strengths

△ Watch

⚠ Risks

Deep analysis

What backs the price

How a revenue dollar becomes profit

Why ROE is —

Debt structure